Full Judgment Text
Text read from the judgment PDF published on the High Court's eCourts portal, through the
Indian High Court Judgments open data set (Dattam Labs,
CC BY 4.0).
The court's own copy is the authoritative text.
HIGH COURT OF JAMMU & KASHMIR AND LADAKH
AT JAMMU
CRM(M) No. 618/2024
Reserved on:07.08.2026
Pronounced on:18.08.2026
Uploaded on:19.08.2026
Whether the operative part or full
judgment is pronounced: Full
Albert David Limited, Registered Office: Block "D",
3rd Floor, Gillander House, 8 Netaji Subhas Road,
Kolkata Through Jammu Regional Sales Manager,
Sh. Dileep Ganjoo, Aged 66 years
S/O Late Shri Hirday Nath Ganjoo, R/o H. No.38,
Subash Nagar Extn.-2 Opp. Petrol Pump, Jammu
…..Petitioner(s)
Through: Mr. Sunil Sethi, Sr. Advocate with
Mr. Shivam Mahajan, Advocate
Mr. Sachin Shukla, Advocate
[Through Virtual Mode]
Mr. Shubham Sharma, Advocate
vs
1. Union Territory of J&K, Through Drugs Inspector,
Kathua.
2. Prop. Krishan Kumar, M/s Hare Rama Hare Krishna
Situated at College Road, Kathua. Through Proprietor.
3. Pradeep Pharmaceutical, 111 Raghunath Pura Jammu
Through its Proprietor.
4. A.H. Enterprises, 3rd Floor, 17, Raghunath Pura Jammu
Through its Proprietor.
5. Sunrise Pharmaceuticals, 25 HSIDC Sector 3 Industrial
Estate Karnal.132001
.….
Respondent(s)
Through: Mr. Raman Sharma, AAG for R-1
Coram:
HON’BLE MR. JUSTICE WASIM SADIQ NARGAL, JUDGE
JUDGMENT
Prayer:
01. The petitioner, through the instant petition filed under Section 482 of the
Code of Criminal Procedure, 1973 akin to Section 528 of the Bharatiya
Nagarik Suraksha Sanhita, 2023 (for short ‗the BNSS‘) seeks quashment of:
CRM(M) No. 618/2024
a) Complaint under section 18(a)(i) read with Section 27(d) of the
Drugs and Cosmetics Act, 1940 titled Drugs Inspector, Kathua
vs. Prop. Krishan Kumar and others pending trial before the
Court of Ld. Chief Judicial Magistrate, Kathua;
b) Order dated 18.02.2020 passed by the Court of Ld. Chief
Judicial Magistrate, Kathua in the impugned Complaint under
section 18(a)(i) read with Section 27(d) of the Drugs and
Cosmetics Act, 1940 titled Drugs Inspector, Kathua vs. Prop.
Krishan others and Kumar cognizance of the whereby impugned
complaint has been taken and process, amongst others, against
the Petitioner Company has been issued;
c) Order dated 27.04.2024 passed by the Court of Ld. Chief Judicial
Magistrate, Kathua in the impugned Complaint under section
18(a)(i) read with Section 27(d) of the Drugs and Cosmetics Act,
1940 titled Drugs Inspector, Kathua vs. Prop. Krishan Kumar and
others whereby the Ld. Chief Judicial Magistrate, Kathua accepted
the personal bond submitted representative on behalf of petitioner
company. However, by same order warrant of arrest was issued
against Petitioner Company by the Ld. Chief Judicial Magistrate,
Kathua.
d) All Subsequent orders/proceedings (after taking cognizance)
being conducted by the Ld. Chief Judicial Magistrate, Kathua in
the impugned complaint under section 18(a)(i) read with Section
27(d) of the Drugs and Cosmetics Act, 1940 titled Drugs
Inspector, Kathua vs. Prop. Krishan Kumar and others, being
totally illegal, in utter contravention of the Drugs and Cosmetics
Act, 1940 and rules framed thereunder and complete misuse and
abuse of process of law.
Brief Facts:
02. The brief facts of the case, as pleaded by the petitioner, are that the
petitioner is a pharmaceutical company engaged in the manufacture of
pharmaceutical formulations and other pharmaceutical products. The
CRM(M) No. 618/2024
petitioner has invoked the inherent criminal jurisdiction of this Court
under Section 482 of the Code of Criminal Procedure, 1973, seeking
quashing of the impugned complaint, the order dated 18.02.2020
whereby cognizance was taken, the subsequent proceedings arising
therefrom and the order dated 27.04.2024 passed by the learned Chief
Judicial Magistrate, Kathua.
03. It is the case of the petitioner Company that respondent No.1, Drug
Inspector, Kathua, conducted a routine inspection on 27.04.2011 of the
premises of respondent No.2, namely, M/s Hare Rama Hare Krishna, a
chemist/drug outlet situated at Kathua and lifted samples of four drugs,
namely, (i) ACCFENAC-P, (ii) Serazo, (iii) Foligem and (iv) ADISTM.
The sample of ADISTM, comprising needles bearing Batch No. 4752,
manufacturing date 2007/08, expiry date 2012/07 and Manufacturing
Licence No. 28/14/90, manufactured by the petitioner Company, was
divided into four portions and duly sealed by the Drug Inspector. A copy
of Form No. 17 along with a sealed portion of each sample, including the
sample of ADISTM, was handed over to respondent No.2 against proper
receipt.
04. It is further pleaded that on 28.04.2011, the Drug Inspector filled up
Form No. 18, namely, the memorandum to the Government Analyst,
and forwarded one sealed portion of the sample of ADISTM to the
Government Analyst, CFDL, Kathua, for testing. The Drug Inspector
thereafter received Test Report No. CFDL/LS/Act/Tests/NC/40/A11 dated 30.11.2011 from the Government Analyst, CFDL, Kathua,
CRM(M) No. 618/2024
wherein the sample was reported to have failed the test for sterility and
was accordingly declared not to be of standard quality.
05. It is also contended that after receipt of the report of the Government
Analyst declaring the drug/needles to be not of standard quality, the
Drug Inspector, vide letter dated 13.12.2011, sought from respondent
No.2 the details of the dealer from whom the drug in question had been
purchased, along with the relevant records, including the purchase
record, balance of stock and the list of institutions to which the drug
had been supplied. A copy of the test report was also furnished to
respondent No.2. In response, respondent No.2 disclosed that the drug
in question had been purchased from respondent No.3, a wholesaler of
pharmaceuticals at Raghunath Pura, Jammu.
06. Thereafter, vide letter dated 22.12.2011, the Drug Inspector forwarded
the report of the Government Analyst to respondent No.3 and called
upon him to furnish the details of the dealer from whom the drug had
been purchased, together with the stock position and purchase and sale
records relating to ADISTM manufactured by the petitioner Company.
Respondent No.3, vide letter dated 22.12.2011, informed the Drug
Inspector that the drug in question had been purchased from
respondent No.4, who, in turn, disclosed that the same had been
purchased from respondent No.5, the petitioner Company. Thereafter,
the Drug Inspector, vide letter dated 08.02.2012, directed the petitioner
Company to furnish its manufacturing and testing records, stock
position and purchase and sale records relating to ADISTM.
CRM(M) No. 618/2024
07. The further case of the petitioner is that upon receipt of the
communication dated 08.02.2012 from the Drug Inspector, it furnished
the requisite details to the Assistant Controller, Drugs and Food
Control Organization, Kathua, vide communication dated 21.02.2012.
The petitioner Company also informed the Drug Inspector that, upon
receipt of the aforesaid communication, it had, as a precautionary
measure, informed respondent No.5 through telegram and registered
letter to withdraw the stocks of the drug from the market. It was further
stated that the petitioner Company had checked the inputs,
manufacturing process and control samples through its Quality
Assurance Department and that the samples had passed all tests,
including the sterility test. The petitioner Company, therefore, disputed
the findings of the Government Analyst and, vide communication
dated 21.02.2012, notified the Drug Inspector of its intention to adduce
evidence in controversion of the Government Analyst's report in terms
of Section 25(3) of the Drugs and Cosmetics Act, 1940, with a request
that the sample be retested by the Director, Central Drugs Laboratory,
Kolkata.
08. Thereafter, the Screening Committee of the office of the Deputy
Controller, Drugs and Food Control Organization, J&K, recommended
that the sample be sent to the Central Drugs Laboratory, Kolkata, for
reanalysis/retesting. Based upon the said recommendation, respondent
No.1 filed the impugned complaint on 14.05.2012 before the Court of
learned Chief Judicial Magistrate, Kathua under Section 18(a)(i) read
with Section 27(d) of the Drugs and Cosmetics Act, 1940 against
CRM(M) No. 618/2024
respondent Nos.2 to 4 as well as the petitioner Company. In the said
complaint, the Drug Inspector also prayed that the sample portion of
the drug in question be sent to the Central Drugs Laboratory, Kolkata,
for reanalysis under Section 25 of the Act, stating that the concerned
accused had notified his intention to have the sample retested.
09. It is submitted that despite institution of the impugned complaint on
14.05.2012, no effective order was passed thereon. On 14.01.2013, the
learned Magistrate called for a report from the concerned Court Clerk
and observed that, as per the record, the complaint appeared to have
been presented on 14.05.2012 and that one of the samples had been
referred for retesting, for which the report was awaited. Accordingly, a
direction was issued to the concerned Court Clerk to send a reminder in
that regard. Thereafter, no effective proceedings took place except the
issuance of reminders to the Director, Central Drugs Laboratory,
Kolkata.
Eventually,
the
Director-in-Charge,
Central
Drugs
Laboratory, Kolkata, submitted a report dated 25.10.2016, which was
received by the Court on 11.11.2016, stating that, upon verification of
the records of the Laboratory, no such sample had been received from
the Court of the learned Chief Judicial Magistrate, Kathua.
10. In view of the aforesaid report of the Director-in-Charge, Central Drugs
Laboratory, Kolkata, the learned Magistrate, vide order dated
06.07.2017, directed the Drug Inspector, who was present in Court, to
take necessary steps in light of the report dated 25.10.2016 so that
appropriate orders could thereafter follow in the matter. Despite the
aforesaid direction, the impugned complaint remained pending without
CRM(M) No. 618/2024
any effective proceedings, and it was only on 18.02.2020 that the
learned Magistrate passed the impugned order whereby cognizance of
the complaint was taken against all the accused persons, including the
petitioner Company, notwithstanding the absence of any report of
reanalysis/retesting from the Central Drugs Laboratory, Kolkata.
11. It is borne out from the record that, along with the impugned complaint, a
sample portion of the drug in question was stated to have been produced
before the learned Magistrate and a prayer was made by the complainant
for its transmission to the Central Drugs Laboratory, Kolkata for
reanalysis. However, the report dated 25.10.2016 issued by the Directorin-Charge, Central Drugs Laboratory, Kolkata, records that no such
sample had been received by the Laboratory from the Court of the learned
Chief Judicial Magistrate, Kathua. Thus, while the sample was stated to
have been produced before the learned Magistrate, the record does not
disclose that the same was ultimately received by the Central Drugs
Laboratory for reanalysis.
12. During the pendency of the aforesaid proceedings, the petitioner
Company, through its authorized representative, appeared before the
learned Magistrate on 27.04.2024 and furnished a personal bond in the
sum of Rs.50,000/-, which was accepted by the learned Magistrate. By the
same order, however, the learned Magistrate directed issuance of warrants
of arrest against accused Nos. 3, 4 and 5, including the petitioner
Company, in the sum of Rs.10,000/- each, to secure their presence. The
petitioner Company, being arrayed as accused No.5, has also called in
question the aforesaid order in the instant petition. The petitioner has
CRM(M) No. 618/2024
further referred to the subsequent order dated 29.06.2024 whereby its
appearance through an authorized representative was questioned by the
learned Magistrate.
13. It is submitted that the learned Magistrate failed to appreciate that the
Director-in-Charge,
Central
Drugs
Laboratory,
Kolkata,
had
categorically informed the Court, vide report dated 25.10.2016, that
upon verification of the records of the Laboratory, no sample had ever
been received from the Court of the learned Chief Judicial Magistrate,
Kathua for re-testing. It is, therefore, the specific case of the petitioner
Company that, in the absence of any report of re-testing/reanalysis
from the Central Drugs Laboratory, Kolkata, the learned Magistrate
ought to have proceeded further in accordance with law instead of
taking cognizance of the complaint and issuing process against the
accused persons. The petitioner Company further submits that the
learned Magistrate thereafter continued with the proceedings in the
impugned complaint despite the absence of any report of retesting/reanalysis from the Central Drugs Laboratory, Kolkata, which,
according to the petitioner, was contrary to the statutory scheme
contemplated under the Drugs and Cosmetics Act, 1940.
14. It is further submitted that the petitioner Company has challenged the
impugned complaint on the ground that the same is illegal,
fundamentally defective and contrary to the provisions of the Drugs
and Cosmetics Act, 1940 and the settled principles of law. The
petitioner has also assailed the order dated 18.02.2020 whereby, despite
the aforesaid position having been noticed on the record, the learned
CRM(M) No. 618/2024
Magistrate proceeded to take cognizance of the complaint and issue
process against the petitioner Company. It is contended that cognizance
was taken after an unexplained delay of nearly eight years from the date
of institution of the complaint on 14.05.2012, without the report of
reanalysis/retesting from the Central Drugs Laboratory, Kolkata, and
without addressing the material irregularities and alleged statutory noncompliance pointed out by the petitioner. According to the petitioner
Company, continuation of the proceedings in such circumstances
amounts to abuse of the process of law and, therefore, the impugned
complaint, the order dated 18.02.2020 and the subsequent proceedings
arising therefrom, including the order dated 27.04.2024, deserve to be
quashed in the interest of justice.
Arguments on behalf of the petitioner:
15. Mr. Sunil Sethi, learned Senior Counsel appearing for the petitioner, at
the outset, has drawn the attention of this Court to the impugned order
dated 18.02.2020 passed by the learned Chief Judicial Magistrate,
Kathua in the complaint under Section 18(a)(i) read with Section 27(d)
of the Drugs and Cosmetics Act, 1940. Learned Senior Counsel
submitted that the complaint was instituted on 14.05.2012 and that
cognizance came to be taken only on 18.02.2020, despite the fact that
no report of reanalysis/retesting had been received from the Central
Drugs Laboratory, Kolkata.
16. It is also submitted that Section 25(3) of the Drugs and Cosmetics Act,
1940 makes it clear that a report of the Government Analyst constitutes
evidence of the facts stated therein and becomes conclusive unless the
CRM(M) No. 618/2024
person from whom the sample was taken, within twenty-eight days of
receipt of a copy of such report, notifies in writing the Inspector or the
Court before which the proceedings are pending of his intention to
adduce evidence in controversion of the report.
17. Relying upon the aforesaid statutory provision, learned Senior Counsel
drew the attention of the Court to the communication dated 21.02.2012
placed on record, the perusal whereof reveals that the petitioner
Company had, within the aforesaid statutory period, notified the
concerned Drug Inspector in writing of its intention to adduce evidence
in controversion of the report of the Government Analyst under Section
25(3) of the Act. The petitioner Company had also specifically
expressed its intention to have the sample retested by the Director,
Central Drugs Laboratory, Kolkata and to obtain the report thereof in
accordance with the provisions of the Act.
18. It is further submitted that the petitioner Company had itself tested its
control samples through its Quality Assurance Department and the
samples had passed the sterility test. The petitioner, therefore, disputed
the findings of the Government Analyst and sought retesting in
accordance with the statutory mechanism. According to learned Senior
Counsel, the sample portion produced before the learned Magistrate
was required to be dealt with in accordance with Section 25(4) of the
Act so as to enable the petitioner to avail its valuable statutory right of
obtaining a report from the Central Drugs Laboratory.
19. It is also contended that, despite the aforesaid position, the sample was
never received by the Central Drugs Laboratory, Kolkata. Reference was
CRM(M) No. 618/2024
made to the report dated 25.10.2016 of the Director-in-Charge, Central
Drugs Laboratory, Kolkata, which categorically recorded that, upon
verification of the records, no such sample had been received by the
Laboratory from the Court of the learned Chief Judicial Magistrate,
Kathua. It was, therefore, contended that the petitioner was deprived of
the opportunity of having the sample tested by the Central Drugs
Laboratory and thereby lost a valuable statutory right available under
Section 25 of the Act.
20. Mr. Sunil Sethi, learned senior counsel for the petitioner, has submitted
that where an accused is deprived of the valuable statutory right
conferred by Sections 25(3) and 25(4) of the Act to have the sample
tested by the Central Drugs Laboratory, despite having duly notified his
intention to controvert the report of the Government Analyst, such
deprivation causes serious prejudice to the defence and continuation of
the criminal proceedings in such circumstances would amount to an
abuse of the process of law.
21. Learned senior counsel has further submitted that where the accused
has exercised the statutory right to have the sample tested by the
Central Drugs Laboratory within the prescribed period, but the sample
is not sent or tested before expiry of its shelf life on account of delay
attributable to the prosecution or the authorities, the accused is
effectively deprived of the valuable right of re-testing and is thereby
seriously prejudiced in his defence. It is, therefore, contended that the
prosecution cannot be permitted to proceed on the basis of the earlier
report when the statutory opportunity to challenge the same has been
CRM(M) No. 618/2024
rendered incapable of exercise.
22. From a bare perusal of the order taking cognizance passed by the Court
below, it is apparent that the complaint was instituted on 14.05.2012
and that cognizance was taken after a gap of nearly eight years, on
18.02.2020, despite no such report having been received from the
Central Drugs Laboratory, Kolkata. In the absence of any such report
having been received by the Court, learned Senior Counsel contended
that the learned Magistrate ought not to have proceeded to take
cognizance and issue process under the Drugs and Cosmetics Act,
1940.
23. It is further submitted that the impugned order dated 18.02.2020 does
not adequately deal with the fact that the Central Drugs Laboratory had
not received the sample for retesting and nevertheless proceeded to take
cognizance on the basis of the Government Analyst's report. According
to learned Senior Counsel, once the petitioner had exercised its
statutory right to controvert the Government Analyst's report and the
sample was thereafter not subjected to the contemplated retesting,
continuation of the prosecution without addressing the resultant
prejudice to the petitioner would amount to abuse of the process of law.
24. The learned Senior Counsel for the petitioner further submits that the
sample in question had a manufacturing date of 2007/08 and an expiry
date of July 2012. The shelf life of the sample had, therefore, expired
long before the impugned order dated 18.02.2020, and the sample could
no longer be subjected to meaningful retesting at this stage. It is thus
contended that the very purpose of preserving the petitioner's statutory
CRM(M) No. 618/2024
right to have the sample tested by the Central Drugs Laboratory has
been rendered incapable of fulfillment and that continuation of the
prosecution would cause serious prejudice to the petitioner.
Reply on behalf of the Official Respondent:
25. Mr. Raman Sharma, learned AAG appearing for the official respondent,
has filed objections wherein it is contended that the impugned complaint
has been instituted under Section 18(a)(i) read with Section 27(d) of the
Drugs and Cosmetics Act, 1940, on the basis of the report of the
Government Analyst declaring the drug in question to be not of standard
quality on account of its having failed the sterility test. It is submitted that
the allegations contained in the complaint prima facie disclose
commission of the offences alleged against the petitioner Company and
the other accused persons.
26. Learned AAG has further submitted that the allegations in the complaint
pertain to the manufacture, sale and distribution of a drug allegedly not
conforming to the prescribed standards and, therefore, involve a matter
concerning public health. It is contended that the petitioner has raised
disputed questions of fact which cannot appropriately be adjudicated in
proceedings invoking the inherent jurisdiction of this Court and are
matters which ought to be considered by the learned trial Court in the
course of the trial.
27. With regard to the petitioner's contention regarding re-testing of the
sample, learned AAG has submitted that, along with the complaint, the
complainant had produced the sample portion of the drug before the
learned Magistrate and had specifically prayed for its being sent to the
CRM(M) No. 618/2024
Central Drugs Laboratory, Kolkata, for reanalysis under Section 25 of the
Act. It is contended that Section 25(4) confers discretion upon the Court
to cause the sample produced before the Magistrate to be sent to the
Central Drugs Laboratory for test or analysis. Learned AAG has further
submitted that the petitioner did not appear before the learned Magistrate
after institution of the complaint and had also not responded to the
communications issued by the Drug Inspector seeking the relevant
manufacturing, stock, purchase and sale records.
28. Learned AAG has also submitted that the report dated 25.10.2016
issued by the Director-in-Charge, Central Drugs Laboratory, Kolkata,
stating that no such sample had been received by the Laboratory, was
not received by the office of the complainant. It is further contended
that the proceedings cannot be quashed merely on the basis of the
assertions made by the petitioner, particularly when the allegations
concern an offence having a bearing upon public health. The learned
counsel has, accordingly, prayed for dismissal of the present petition
and for permitting the prosecution to proceed before the learned trial
Court in accordance with law.
Legal Analysis:
29. Heard learned Senior Counsel appearing for the petitioner and learned
AAG appearing for the official respondent and perused the record.
30. Before adverting to the issues which arise for determination in the instant
matter, it would be appropriate to notice certain facts emerging from the
record which are not in dispute. The sample of ADIS Needles, Batch No.
4752, manufactured by the petitioner Company, was drawn by the Drug
CRM(M) No. 618/2024
Inspector and was subjected to analysis by the Government Analyst,
whose report dated 30.11.2011 declared the sample to be not of standard
quality on account of failure of the sterility test. The said report was
thereafter communicated to the petitioner Company, which, vide its
communication dated 21.02.2012, within the prescribed period of twentyeight days, notified its intention to controvert the report and specifically
sought re-testing of the sample by the Director, Central Drugs Laboratory,
Kolkata, in terms of Section 25(3) and (4) of the Act.
31. It is also borne out from the record that the complaint came to be
instituted on 14.05.2012 and that the complainant itself sought
transmission of the sample to the Central Drugs Laboratory, Kolkata, for
re-analysis. The record further indicates that the sample was stated to have
been sent by the learned Trial Court for such re-testing, but the report of
the Central Drugs Laboratory was not received for more than four years.
Eventually, vide communication dated 25.10.2016, the Director-inCharge, Central Drugs Laboratory, Kolkata, informed the learned Court
that no such sample had been received from the Court of the learned
Chief Judicial Magistrate, Kathua. Despite the aforesaid position, no
report of re-analysis was thereafter obtained and the learned Magistrate
ultimately proceeded to take cognizance and issue process vide order
dated 18.02.2020 on the basis of the earlier report of the Government
Analyst.
32. Thus, the controversy before this Court essentially arises from the manner
in which the statutory mechanism under Section 25 of the Drugs and
Cosmetics Act was dealt with after the petitioner exercised its right to
CRM(M) No. 618/2024
controvert the Government Analyst’s report. The questions that arise for
consideration are, therefore, not merely whether such right was exercised,
but also whether the subsequent statutory procedure was duly followed,
whether the earlier report could still be relied upon after the failure of reanalysis, whether the limited shelf life of the sample and the delay in the
proceedings had any legal consequence, and whether the manner in which
the proceedings were thereafter continued can be sustained in law. These
aspects discussed hereinabove are required to be dealt in detail. Upon
consideration of the pleadings, the material placed on record and the
submissions advanced by learned counsel for the parties, the following
questions arise for determination:
“Question No. 1: Whether the petitioner was deprived of its
statutory right under Sections 25(3) and 25(4) of the Drugs and
Cosmetics Act, 1940, upon timely seeking re-analysis of the
sample by the Central Drugs Laboratory?
Question No. 2: Whether, after the petitioner exercised its
statutory right to have the sample re-tested by the Central Drugs
Laboratory, the learned Trial Court could proceed on the basis of
the earlier report of the Government Analyst?
Question No. 3: What procedure were the learned Magistrate and
the Drug Inspector required to follow under Section 25 of the Drugs
and Cosmetics Act, 1940, after the petitioner had notified its intention
to controvert the Government Analyst's report and sought reanalysis/re-testing of the sample by the Central Drugs Laboratory?
Question No. 4: Whether a drug sample, after expiry of its shelf
life, can be meaningfully re-tested or relied upon for sustaining
the prosecution?
Question No. 5: Whether the learned Trial Court failed to ensure
timely and effective compliance with the statutory procedure
under the Drugs and Cosmetics Act, having regard to the object of
the Act and its serious public health implications?
CRM(M) No. 618/2024
Question No. 6: To whom is the delay of almost eight years, from
the institution of the complaint on 14.05.2012 till the passing of
the impugned order dated 18.02.2020, attributable, and what
consequence follows therefrom?
Question No. 7: Whether the prolonged pendency of the
prosecution, violates the requirement of a fair and speedy trial
under Article 21 of the Constitution of India, particularly when
the prosecution concerns a matter having serious ramifications for
public health?
Question No. 8: Whether, in the facts of the present case,
continuation of the prosecution amounts to abuse of the process of
law warranting exercise of the inherent jurisdiction of this Court
under Section 482 of the Code of Criminal Procedure, 1973 akin to
Section 528 of the Bharatiya Nagarik Suraksha Sanhita, 2023 (for
short ‗the BNSS‘)?
Questions No. 1 - Whether the petitioner was deprived of its statutory right under Sections
25(3) and 25(4) of the Drugs and Cosmetics Act, 1940, upon timely seeking re-analysis of the
sample by the Central Drugs Laboratory?
33. Before examining the facts of the present case, it would be apposite to
notice the statutory scheme contained in Section 25 of the Drugs and
Cosmetics Act, 1940, which prescribes a specific mechanism governing
the evidentiary value of the report of the Government Analyst and the
procedure to be followed where the person concerned intends to adduce
evidence in controversion of such report. For facility of reference, Section
25 of the Drugs and Cosmetics Act, 1940 is reproduced as under:
―25. Reports of Government Analysts.—
(1) The Government Analyst to whom a sample of any drug 3 [or
cosmetic] has been submitted for test or analysis under sub-section (4)
of section 23, shall deliver to the Inspector submitting it a signed report
in triplicate in the prescribed form.
(2) The Inspector on receipt thereof shall deliver one copy of the report
CRM(M) No. 618/2024
to the person from whom the sample was taken 4 [and another copy to
the person, if any, whose name, address and other particulars have
been disclosed under section 18A], and shall retain the third copy for
use in any prosecution in respect of the sample.
(3) Any document purporting to be a report signed by a Government
Analyst under this Chapter shall be evidence to the facts stated therein,
and such evidence shall be conclusive unless the person from whom the
sample was taken 5 [or the person whose name, address and other
particulars have been disclosed under section 18A] has, within twentyeight days of the receipt of a copy of the report, notified in writing the
Inspector or the Court before which any proceedings in respect of the
sample are pending that he intends to adduce evidence in controversion
of the report.
(4) Unless the sample has already been tested or analyzed in the
Central Drugs Laboratory, where a person has under sub-section (3)
notified his intention of adducing evidence in controversion of a
Government Analyst‗s report, the Court may, of its own motion or in
its discretion at the request either of the complainant or the accused,
cause the sample of the drug 3 [or cosmetic] produced before the
Magistrate under subsection (4) of section 23 to be sent for test or
analysis to the said Laboratory, which shall make the test or analysis
and report in writing signed by, or under the authority of, the Director
of the Central Drugs Laboratory the result thereof, and such report
shall be conclusive evidence of the facts stated therein.
(5) The cost of a test or analysis made by the Central Drugs
Laboratory under sub-section (4) shall be paid by the complainant or
accused as the Court shall direct.‖
34. The significance of the aforesaid statutory mechanism is that the report
of the Government Analyst is not to attain conclusiveness where the
person concerned, within twenty-eight days of receipt of a copy thereof,
notifies in writing his intention to adduce evidence in controversion of
the same. The statute consequently provides a further mechanism for
analysis of the sample by the Central Drugs Laboratory, whose report is
CRM(M) No. 618/2024
accorded conclusive evidentiary value under sub-section (4). The right
so conferred upon the person concerned is, therefore, a substantive
statutory safeguard and not a mere procedural formality.
35. In the present case, the Government Analyst, vide report dated
30.11.2011, declared the sample of ADIS Needles, Batch No. 4752, to
be not of standard quality on account of failure of the sterility test. The
petitioner Company, upon receipt of the said report, responded vide
communication dated 21.02.2012 and, within the prescribed period of
twenty-eight days, expressly notified the Assistant Controller, Drug &
Food Control Organisation along with the Drug Inspector of its
intention to adduce evidence in controversion of the Government
Analyst's report and sought re-testing of the sample through the
Director, Central Drugs Laboratory. The relevant part of the said
communication reads as under:
―2. Further we investigated samples in our QA department which passes
in sterility test hence we do not agree with the findings of the Govt.
Analyst and wish to challenge the report.
3. Be that as it may, we intend to adduce evidence in contravention of the
said report U/S 25(3) of the Drugs and Cosmetic Act, 1940, within the
prescribed period as laid down therein based on our receipt of the report.
Such adducing is done to get the sample re-tested through the Director,
CDL and not the Govt. Analyst and the report there upon to be sent in
Form-2 as per provision of law.
This intimation may please be considered as is ‗notified in writing‘ to
concerned Inspector of Drugs as per provision laid down U/S 25(3) of the
said Act.‖
36. The aforesaid communication leaves little scope for doubt that the
petitioner had not merely disputed the findings of the Government
Analyst, but had consciously and expressly invoked the statutory
mechanism under Section 25(3) and sought re-testing of the sample by
the Director, Central Drugs Laboratory. The subsequent record also
CRM(M) No. 618/2024
demonstrates that this request was acted upon by the complainant side,
as the Screening Committee of the Drugs and Food Control
Organization recommended that the sample be sent to the Central
Drugs Laboratory, Kolkata, for reanalysis/retesting. The complaint
instituted on 14.05.2012 itself contained a specific prayer for sending
the sample to the Central Drugs Laboratory under Section 25 of the
Act. Thus, the statutory right exercised by the petitioner was duly
recognised in the proceedings.
37. The Hon’ble Supreme Court in M/s. Medicamen Biotech Ltd. & Anr.
v. Rubina Bose, (2008) 7 SCC 196, while dealing with the consequence
of failure to facilitate timely re-testing of a drug sample and deprivation
of the valuable right available under Sections 25(3) and 25(4) of the Act,
has held as under:
―18. We find that this judgment helps the case of the appellant rather than
that of the respondent because in spite of two communications from the
appellant that it intended to adduce evidence to controvert the facts given
in the report of the Government Analyst, the fourth sample with the
Magistrate had not been sent for re-analysis. The observations in Amery
Pharmaceuticals's case (supra) are also to the same effect. We find that
the aforesaid interpretation supports the case of the appellants inasmuch
they had been deprived of the right to have the fourth sample tested from
the Central Drugs Laboratory. It is also clear that the complaint had been
filed on the 2nd July 2002 which is about a month short of the expiry date
of the drug and as such had the accused appellant appeared before the
Magistrate even on 2nd July 2002 it would have been well nigh impossible
to get the sample tested before its expiry. In the affidavit filed to the
petition by Dr. D. Rao, Deputy Drugs Controller, and in arguments
before us, it has been repeatedly stressed that the delay in sending of the
sample to the Central Drugs Laboratory had occurred as the appellant had
avoided service of summons on it till 9th May 2005. This is begging the
question. We find that there is no explanation as to why the complaint
itself had been filed about a month before the expiry of the shelf life of the
drug and concededly the filing of the complaint had nothing to do with the
appearance of the accused in response to the notices which were to be
issued by the Court after the complaint had been filed. Likewise, we
observe that the requests for retesting of the drug had been made by the
appellant in August/September 2001 as would be clear from the facts
already given above and there is absolutely no reason as to why the
complaint could not have been filed earlier and the fourth sample sent for
CRM(M) No. 618/2024
retesting well within time. We are, therefore, of the opinion that the facts
of the case suggest that the appellants have been deprived of a valuable
right under Section 25(3) and 25(4) of the Act which must necessitate the
quashing of the proceedings against them.‖
38. The Hon’ble Supreme Court, while dealing with the analogous
statutory mechanism under the Insecticides Act, 1968, in State of
Haryana v. Unique Farmaid (P.) Ltd. & Ors., (1999) 8 SCC 190, has
also held that as under:
―12. It cannot be gainsaid, therefore, that the respondents in these appeals
have been deprived of their valuable right to have the sample tested from
the Central Insecticides Laboratory under sub- section (4) of Section 24 of
the Act. Under sub-section (3) of Section 24 report signed by the
Insecticide analyst shall be evidence of the facts stated therein and shall be
conclusive evidence against the accused only if the accused do not, within
28 days of the receipt of the report, notify in writing to the Insecticides
Inspector or the Court before which proceedings are pending that they
intend to adduce evidence to controvert the report. In the present cases
Insecticide Inspector was notified that the accused intended to adduce
evidence to controvert the report. By the time the matter reached the court,
shelf life of the sample had already expired and no purpose would have
been served informing the court of such an intention. The report of the
Insecticide Analyst was, therefore, not conclusive. A valuable right had
been conferred on the accused to have the sample tested from the Central
Insecticides Laboratory and in the circumstances of the case accused have
been deprived of that right, thus, prejudicing them in their defence.‖
39. The principle emerging from the aforesaid decisions is that once the
statutory right to controvert the analyst's report is exercised within the
prescribed period, the accused cannot subsequently be deprived of the
corresponding opportunity of having the sample examined by the
Central Laboratory on account of a failure in the statutory process. In
the present case, the petitioner exercised the right on 21.02.2012, while
the sample was still within its shelf life and as recorded by the Court of
the learned Chief Judicial Magistrate, Kathua the sample had already
been sent to the Central Drugs Laboratory, Kolkata. However, the
report of the Central Drugs Laboratory was not received which is
evident from a bare perusal of communication dated 25.10.2016, the
CRM(M) No. 618/2024
Director-in-Charge informed the Court that no such sample had been
received from the Court of the learned Chief Judicial Magistrate,
Kathua. The statutory process, therefore, remained incomplete.
40. The failure to obtain the report of the Central Drugs Laboratory cannot,
in the circumstances of the present case, be attributed to any failure on
the part of the petitioner to exercise the right available under Section
25(3). On the contrary, the petitioner had expressly exercised that right
within the prescribed period and had specifically sought re-testing by
the Central Drugs Laboratory. The subsequent failure to secure the
report, despite the sample having been sent by the Court, allegedly,
resulted in deprivation of the very statutory safeguard which the
petitioner had timely invoked. This assumes greater significance as the
sample expired in July, 2012 and therefore, the opportunity of
obtaining a meaningful re-analysis was itself time-sensitive.
41. In view of the aforesaid statutory scheme, the communication dated
21.02.2012 and the principles laid down by the Hon’ble Supreme Court
in Medicamen Biotech and Unique Farmaid, this Court is of the
considered view that the petitioner had duly exercised the statutory
right under Section 25(3) and had invoked the mechanism
contemplated under Section 25(4). The failure thereafter to secure the
report of the Central Drugs Laboratory deprived the petitioner of the
valuable opportunity which the statute had specifically conferred upon
it. The statutory mechanism, having been invoked within time, could
not be allowed to fail to the prejudice of the petitioner.
Accordingly, Question No. 1 is, answered in favour of the petitioner and
CRM(M) No. 618/2024
against the official respondent.
Question No. 2: Whether, after the petitioner exercised its statutory right to have the sample retested by the Central Drugs Laboratory, the learned Trial Court could proceed on the basis of
the earlier report of the Government Analyst?
42. Section 25 of the Drugs and Cosmetics Act prescribes a specific
statutory mechanism for dealing with a Government Analyst's report
once the person concerned notifies, within the prescribed period, his
intention to adduce evidence in controversion thereof. Under Section
25(4) of the Act, upon such notification, the sample is required to be
sent to the Central Drugs Laboratory for test or analysis and the report
of the said Laboratory is made conclusive evidence of the facts stated
therein. The legislative scheme and intent thus clearly contemplates
that, once the statutory right of re-testing has been invoked, the report
of the Central Drugs Laboratory assumes overriding and conclusive
significance and the earlier report of the Government Analyst cannot be
treated as the final basis for determining the controversy.
43. The Hon'ble Supreme Court in Municipal Corporation of Delhi v.
Ghisa Ram, AIR 1967 SC 970, while considering an analogous
statutory mechanism under the Prevention of Food Adulteration Act,
recognized the importance of the right of the accused to have the
sample analyzed by the superior laboratory and held as under:
“It appears to us that when a valuable right is conferred by s. 13 (2) of
the Act on the vendor to have the sample given to him analysed by the
Director of the Central Food Laboratory, it is to be expected that the
prosecution will proceed in such a manner that that right will not be
denied to him. The right is a valuable one, because the certificate of the
Director supersedes the report of the Public Analyst and is treated as
conclusive evidence of its contents. Obviously, the right has been given
to the vendor in order that, for his, satisfaction and proper defence, he
CRM(M) No. 618/2024
should be able to have the sample kept in his charge analysed by a
greater expert whose certificate is to be accepted by Court as conclusive
evidence. In a case where there is denial of this right on account of the
deliberate conduct of the prosecution, we think that the vendor, in his
trial, is so seriously prejudiced that it would not be proper to uphold his
conviction on the basis of the report of the Public Analyst, even though
that report continues to be evidence in the case of the facts contained
therein.‖
44. In the present case, the petitioner had, within the prescribed period,
notified the Drug Inspector of its intention to controvert the
Government Analyst's report and specifically sought re-testing of the
sample by the Central Drugs Laboratory, Kolkata. The sample was
allegedly, thereafter, sent by the learned Trial Court to the Central
Drugs Laboratory. Once this statutory course had been adopted, the
earlier report of the Government Analyst could not thereafter be treated
as the report upon which the prosecution could finally proceed,
particularly when, the very purpose of sending the sample to the
Central Drugs Laboratory was to obtain the report contemplated under
Section 25(4) of the Act. The Learned Trial Court was required to
obtain the said report before proceeding on the merits of the allegation
against the petitioner.
45. The record, however, shows that the report of the Central Drugs
Laboratory was never received. After waiting for more than four years,
the learned Trial Court received the communication dated 25.10.2016
from the Director-in-Charge, Central Drugs Laboratory, Kolkata,
stating that no such sample had been received from the Court. The
relevant part of the communication has been reproduced here as under:
―With reference to above regarding test report of ADIS Needles, Batch
No. 4752, D/M:08/2007, D/E:07/2012, Manufactured by M/s Albert
David Ltd., 207, New Industrial Area No. 2, Manideep – 462046, Near
CRM(M) No. 618/2024
Bhopal (M P.), it is to inform you that our records have been carefully
checked and found that no such sample was received by this laboratory
for testing from your Hon‘ble Court.‖
46. The said communication could not have resulted in the Court simply
reverting to the earlier Government Analyst's report, because the
statutory process of re-testing had already been invoked and the sample
had been sent for that very purpose. The appropriate course for the
Learned Trial Court was to ascertain what had happened to the sample
and to take effective steps in accordance with law. The mere nonreceipt of the CDL report did not restore the earlier Government
Analyst's report to the position which it occupied before the petitioner
exercised its statutory right.
47. The position becomes even more significant in view of the limited shelf
life of the sample, which expired in July, 2012. By the time the learned
Trial Court ultimately proceeded to take cognizance and issue process
on 18.02.2020, the sample had long ceased to be available for
meaningful re-testing. Thus, the very statutory mechanism through
which the petitioner was entitled to controvert the Government
Analyst's report had been rendered incapable of completion, while the
Court nevertheless proceeded on the basis of the very report which the
petitioner had lawfully chosen to controvert. Such a course would, in
effect, defeat the statutory right conferred under Section 25 and permit
the earlier report to operate as conclusive in circumstances in which the
statutory process had already moved beyond it.
48. Therefore, in the peculiar facts of the present case, the earlier report of
the Government Analyst could not have been treated as a substitute for,
CRM(M) No. 618/2024
or as superseding, the report contemplated under Section 25(4) of the
Act. Once the petitioner had exercised its statutory right and the sample
had been sent for re-testing, the learned Trial Court could not validly
issue process against the petitioner on the basis of the earlier report
without first obtaining the report of the Central Drugs Laboratory or
otherwise addressing the failure of the statutory re-testing mechanism.
The issuance of process on the basis of the earlier Government
Analyst's report, after the statutory mechanism had been invoked and
the sample had become incapable of re-testing, therefore had no legal
sanctity in the peculiar facts of the present case.
Accordingly, Question No. 2 is answered in favour of the petitioner and
against the official respondent.
Question No. 3: What procedure were the learned Magistrate and the Drug Inspector required
to follow under Section 25 of the Drugs and Cosmetics Act, 1940, after the petitioner had
notified its intention to controvert the Government Analyst's report and sought re-analysis/retesting of the sample by the Central Drugs Laboratory?
49. It would be profitable to refer to Section 25 of the Drugs and Cosmetics
Act, 1940, which prescribes a specific procedure to be followed once the
person concerned notifies his intention to controvert the report of the
Government Analyst. In the present case, once the petitioner had
exercised its right under Section 25(3) of the Act, the procedure
contemplated under Section 25(4) was required to be duly followed.
50. The principles laid down by the Hon’ble Supreme Court in M/s.
Medicamen Biotech Ltd. & Anr. v. Rubina Bose, (2008) 7 SCC 196,
as noticed hereinabove, are equally apposite to the present issue
wherein it was held as under:
CRM(M) No. 618/2024
―13…A reading of the aforesaid provisions would reveal that they lay
certain obligations as well as provide safeguards for a person from whom a
drug has been seized for analysis or testing as Section 25(3) specifies that
unless such a person controverts the correctness of the report submitted by
the Government Analyst within 28 days in writing that he intends to
adduce evidence to controvert the report of the Analyst, it would be
deemed to be conclusive evidence of the quality of the drug whereas subsection (4) of Section 25 obliges the Magistrate on the request of the
complainant or the accused or on in his own motion to send the fourth
sample which has been disputed for fresh testing to the Director of the
Central Drugs Laboratory.
14. It is the case of the appellant that despite the fact that the appellant
had repeatedly controverted the accuracy of the report of the Government
Analyst the fourth sample had still not been sent to the Director for retesting and analysis. We find that the argument raised by the learned
counsel for the respondent that the appellant had never expressed a desire
to controvert the report of the Drug Analyst is not correct as is clear from
the letter dated 28th August 2001 addressed to the Assistant Director
General, Government Medical Stores Depot…‖
51. Similarly, the Hon’ble Apex Court in “Northern Mineral Ltd. v Union
of India and Anr.”, 2010 (7) SCC 726, while considering the statutory
mechanism governing the testing of the sample and the consequence of
failure to follow the prescribed procedure, held as under:
―23. Section 24(3) of the Act gives right to the accused to rebut the
conclusive nature of the evidence of Insecticide Analyst by notifying its
intention to adduce evidence in controversion of the report before the
Insecticide Inspector or before Court where proceeding in respect of the
samples is pending. Further the Court has been given power to send the
sample for analysis and test by the Central Insecticides Laboratory of its
own motion or at the request of the complainant or the accused.
24. No proceeding was pending before any Court, when the accused was
served with Insecticide Analyst report, the intention was necessarily
required to be conveyed to the Insecticide Inspector, which was so done by
the appellant and in this background Insecticide Inspector was obliged to
institute complaint forthwith and produce sample and request the court to
send the sample for analysis and test to the Central Insecticides
Laboratory. Appellant did whatever was possible for it. Its right has been
defeated by not sending the sample for analysis and report to Central
Insecticides Laboratory.‖
52. The Court was required to ensure that the sample produced before it
was effectively transmitted to the Central Drugs Laboratory and that
the test or analysis contemplated by the statute was carried out. The
duty did not end by merely mentioning that the sample had been sent
CRM(M) No. 618/2024
for re-testing. The statutory procedure was required to be completed in
substance and within a period in which the sample could still be
meaningfully analysed.
53. In the present case, as recorded by the learned Chief Judicial
Magistrate, Kathua, the Court had sent the sample to the Central Drugs
Laboratory, Kolkata for re-testing. Once the sample had been sent, it
was the bounden duty of the Court to ensure that the sample reached
the laboratory timely and the report was received within the period
during which the validity and shelf life of the sample subsisted. The
Court could not merely continue awaiting the report indefinitely,
particularly when the sample was due to expire in July, 2012 and the
entire statutory mechanism was dependent upon timely analysis of the
very sample in question.
54. The record, however, reveals that the Court continued to await the
report for more than four years and issued reminders to the Central
Drugs Laboratory. When the Laboratory ultimately informed the Court
on 25.10.2016 that no such sample had been received, the matter
required immediate and effective scrutiny. The question which
naturally arose was as to what had happened to the sample after it had
been sent by the Court, at what stage it was lost or failed to reach the
Laboratory and who was responsible for such failure. Such inquiry was
necessary not only for ensuring compliance with the statutory
procedure but also for fixing responsibility for the failure, instead of
allowing the consequences of that failure to fall upon the accused.
55. The learned Magistrate, instead of undertaking such an exercise, vide
CRM(M) No. 618/2024
order dated 06.07.2017 merely directed the Drug Inspector to take
necessary steps in light of the report dated 25.10.2016. Thereafter,
nothing effective appears to have been done. The order dated
18.02.2020 which is impugned in the instant petition also does not
disclose what steps were taken after the communication regarding non
receipt of the sample from the Central Drugs Laboratory was received,
nor does it disclose any inquiry into the whereabouts of the sample or
the circumstances in which it failed to reach the Laboratory.
56. The duty in such circumstances was not confined to the Court alone.
The Drug Inspector, being the complainant and the officer responsible
for setting the statutory machinery in motion, and to ensure that the
procedure contemplated by Section 23 and Section 25 of the Act was
effectively complied with. If the sample had not reached the Central
Drugs Laboratory, it was incumbent upon the complainant and the
Court to ensure that the sample was again dealt with in conformity with
the statutory provision, subject of course to its availability and
condition.
57. The clerical machinery of the Court also had a corresponding role in
ensuring compliance with the directions issued by the Court. The
statutory procedure could not be reduced to a paper exercise, where
reminders were issued for years while the sample's shelf life continued
to run out.
58. The learned Magistrate, however, did not undertake such an exercise
and, after allowing a further period to lapse, ultimately proceeded to
issue process on 18.02.2020 on the basis of the earlier Government
CRM(M) No. 618/2024
Analyst's report. Thus, the very procedure which had been initiated to
protect and give effect to the petitioner's statutory right was not brought
to its logical conclusion. The Court, the clerical staff and the Drug
Inspector in unison were required to act with greater diligence,
particularly because the sample had a limited shelf life and the statutory
scheme itself attached importance to timely testing.
59. The failure to ensure timely transmission, receipt and analysis of the
sample, followed by the failure to ascertain the circumstances in which
the sample did not reach the Central Drugs Laboratory, has resulted in
the statutory procedure being rendered ineffective. The Court,
therefore, could not proceed as though no request for reanalysis had
ever been made.
Question No. 3 is answered accordingly, with the finding that the statutory
procedure required active and timely compliance by the Court and the
complainant machinery, which was not undertaken in the present case.
Question No. 4: Whether a drug sample, after expiry of its shelf life, can be meaningfully retested or relied upon for sustaining the prosecution?
60. The question of shelf life assumes significance in the context of the
statutory right of re-analysis under Section 25 of the Drugs and
Cosmetics Act. The said provision necessarily contemplates that the
sample remains available and capable of being meaningfully tested
when the accused invokes the statutory mechanism. The right to reanalysis cannot be preserved in papers while the sample, by passage of
time, becomes incapable of being subjected to the very test for which
such right was exercised. In the present case, the drug sample
('ADISTM', Batch No. 4752) had an expiry date of 07/2012, which
CRM(M) No. 618/2024
lapsed long before cognizance was taken in 2020.
61. The Hon’ble Apex Court, in “Laborate Pharmaceuticals India Ltd. v.
State of Tamil Nadu [(2018) 15 SCC 93]” while considering
the
significance of shelf life in the context of the statutory right of reanalysis, held as under:
―8. The cognizance of the offence(s) alleged in the present case
was taken on 4th March, 2015 though it appears that the
complaint itself was filed on 28th November, 2012. According to
the appellant the cough syrup had lost shelf life in the month of
November, 2012 itself. Even otherwise, it is reasonably certain
that on the date when cognizance was taken, the shelf life of the
drug in question had expired. The Magistrate, therefore, could
not have sent the sample for reanalysis by the Central
Laboratory
9. All the aforesaid facts would go to show that the valuable right
of the appellant to have the sample analyzed in the Central
Laboratory has been denied by a series of defaults committed by
the prosecution; firstly, in not sending to the appellantmanufacturer part of the sample as required under Section
23(4)(iii) of the Act; and secondly, on the part of the Court in
taking cognizance of the complaint on 4th March, 2015 though
the same was filed on 28th November, 2012. The delay on both
counts is not attributable to the appellants and, therefore, the
consequences thereof cannot work adversely to the interest of the
appellants. As the valuable right of the accused for re-analysis
vested under the Act appears to have been violated and having
regard to the possible shelf life of the drug we are of the view that
as on date the prosecution, if allowed to continue, would be a
lame prosecution‖
62. The same principle finds support from the judgment of the Punjab and
Haryana High Court in ‘Shiv Narain Bansal and Anr. v. State of
Haryana and Anr.’, 1996 Cri LJ 338, while considering the
consequence of failure to send the sample to the Central Drugs
Laboratory within its shelf life, the Court held as under:
“12. In view of my discussion above, I find force in the argument
of the learned counsel for the petitioners that the petitioners had
CRM(M) No. 618/2024
informed the Drugs Inspector in time for sending their sample to
get it tested from the Central Drugs Laboratory but it was the
fault of the Inspector that the sample could not be sent to the
Central Drugs Laboratory in time and it was sent only after its
expiry date. The petitioners obviously have been deprived of their
right given to them under Section 25(3) of the Act.”
63. The principle emerging from the aforesaid decisions is squarely
attracted to the present controversy. The statutory right of the petitioner
was exercised while the sample was still within its shelf life. Once the
sample was required to be sent for re-analysis pursuant to such exercise
of the statutory right, it was incumbent upon the authorities concerned
and the Court to ensure that the process was completed before the
expiry of the sample. The subsequent expiry of the sample could not
render the right so exercised incapable of enforcement.
64. In the present case, the sample had an expiry date of July, 2012,
whereas the report of the Central Drugs Laboratory, Kolkata was not
received within that period. Rather, after more than four years, the
Central Drugs Laboratory informed the Court on 25.10.2016 that no
such sample had been received by them. The consequence was
irreversible, as by then the shelf life of the sample had expired and the
opportunity to obtain the statutory re-analysis had been lost. Such loss
of opportunity cannot be treated as a mere procedural lapse, since it
directly affects the petitioner's ability to controvert the Government
Analyst's report through the mechanism specifically provided by the
statute.
CRM(M) No. 618/2024
65. The expiry of the sample also assumes significance because the inability
to undertake re-analysis at this stage cannot be attributed to the
petitioner, who had already exercised its statutory right before expiry of
the sample. The subsequent passage of time, during which the sample
was not received by the Central Drugs Laboratory and no effective
steps were taken to secure its timely examination, cannot operate to the
prejudice of the petitioner. To permit the prosecution to rely upon the
earlier report in such circumstances would effectively deprive the
petitioner of a statutory safeguard which was available to it when the
right was exercised.
66. The statutory scheme of the Drugs and Cosmetics Act assumes
particular significance in this regard, as the procedure contemplated
thereunder is inherently time-bound and the efficacy of the statutory
right of re-analysis is closely connected with the shelf life of the drug.
Timely action by the authorities is therefore essential to preserve the
sample for meaningful examination and to ensure that the statutory
right of the accused is not rendered illusory by the passage of time.
Furthermore, the judgments referred in the preceding questions have
also emphasized the importance of ensuring that the drug is tested
within its prescribed shelf life.
67. Therefore, once the sample expired in July, 2012 without its having
been subjected to the re-analysis contemplated under Section 25(4), the
statutory opportunity of obtaining the Central Drugs Laboratory's
report stood irreversibly lost. A sample whose shelf life has expired
cannot, in the peculiar facts of the present case, be treated as capable of
CRM(M) No. 618/2024
meaningful re-testing, nor can the consequence of the lost opportunity
be fastened upon the petitioner.
Accordingly, Question No. 4 is answered in favour of the petitioner and
against the official respondent.
Question No. 5: Whether the learned Trial Court failed to ensure timely and effective
compliance with the statutory procedure under the Drugs and Cosmetics Act, having regard to
the object of the Act and its serious public health implications?
68. The Drugs and Cosmetics Act, 1940 is intended to regulate the import,
manufacture, distribution and sale of drugs and to ensure that drugs
made available to the public conform to the prescribed standards of
quality and safety. The object of the legislation has a direct bearing upon
public health and the statutory procedure prescribed thereunder is,
therefore, required to be complied with diligently and within the time
contemplated by the Act. The public-health dimension of the enactment
has also been judicially recognised in Vikas Rambal v. State, Crl.O.P.
No.11184/2019, decided on 12.10.2022, wherein the High Court of
Madras, while referring to the Statement of Objects and Reasons of the
Drugs and Cosmetics (Amendment) Act, 1982, observed as under:
―21. The Drugs and Cosmetics Act, 1940 came into force on 10.04.1940.
It is an existing law when the Constitution came into force. In the year
1982 there was an amendment to this Act, the statement of Objects and
Reasons for the said Amendment, explains the purpose of the Act as
below:Amendment Act 68 of 1982- Statement of Objects and Reasons:- The
Drugs and Cosmetics Act, 1940, regulates the import into, manufacture,
distribution and sale of drugs and cosmetics in the country. The problems
of adulteration of drugs and also of production of spurious and substandard drugs are posing serious threat to the health of the community.
It is, therefore considered necessary to amend the Drugs and Cosmetics,
CRM(M) No. 618/2024
Act, so as to impose more stringent penalties on the anti- social elements
indulging in the manufacture or sale of adulterated or spurious drugs or
drugs not of standard quality which are likely to cause death or grievous
hurt to the user. This opportunity is also being availed of to incorporate
certain other provisions on the other aspects/judis of effective control on
the manufacture, distribution, sale of drugs and cosmetics on the basis of
experience gained in the working of the Act.‖
69. The object of the enactment also has to be viewed in the context of the
fundamental right to life guaranteed under Article 21 of the Constitution
of India. The right to life is not confined to mere physical existence, but
encompasses the right to live with dignity and includes within its ambit
the protection of health and well-being. Every person, as a consumer of
medicines, is entitled to expect that drugs made available for human
consumption conform to the prescribed standards of quality and are not
sub-standard or otherwise unsafe. The manufacture and distribution of
drugs which fail to meet the prescribed standards, therefore, carries a
direct bearing upon public health and, consequently, implicates the
constitutional concern underlying Article 21. The statutory safeguards
contained in the Drugs and Cosmetics Act must accordingly be
understood as serving not merely a regulatory purpose, but also as an
important legislative mechanism for protecting the health and life of
persons who may be required to consume such drugs.
70. The aforesaid object assumes particular significance in the facts of the
present case. Once the petitioner had disputed the report of the
Government Analyst and the sample was sent by the Court to the
Central Drugs Laboratory for re-testing as recorded by the learned
Chief Judicial Magistrate in January, 2013, it was incumbent upon the
CRM(M) No. 618/2024
Court to ensure that the sample actually reached the Laboratory and
that the statutory process was completed expeditiously. This was all the
more necessary as the sample had a limited shelf life and was due to
expire in July, 2012. The statutory mechanism could not, therefore,
have been allowed to remain in abeyance merely by awaiting the report
of the Central Drugs Laboratory.
71. The record, however, discloses that the complaint was instituted on
14.05.2012 and the matter thereafter remained pending awaiting the
report of the Central Drugs Laboratory. The learned Trial Court itself
noticed that the sample had been referred for re-testing and that the
report was awaited and directed the concerned clerk to send a reminder.
Thereafter, instead of taking effective measures to ascertain whether the
sample had actually reached the Laboratory and, if not, to ensure its
transmission, the matter continued to linger through reminders.
72. The matter was permitted to remain pending until 18.02.2020, when
the learned Trial Court proceeded to issue process on the basis of the
earlier report of the Government Analyst, without securing the report of
the Central Drugs Laboratory or examining the circumstances leading
to the non-receipt of the sample.
73. In the considered view of this Court, such an approach was contrary to
the mandate and spirit of the Drugs and Cosmetics Act. Where the very
object of the legislation is to protect public health by ensuring the
quality and safety of drugs, the Court is required to ensure that the
statutory process is carried forward with due expedition and
effectiveness. In prosecutions under this Act, where time is strictly of
CRM(M) No. 618/2024
the essence, mere issuance of reminders, without ensuring that the
sample reached the Central Drugs Laboratory within its shelf life,
defeated the very purpose of the re-testing mechanism and ultimately
rendered the statutory process incapable of achieving its object.
Question No. 5 is answered accordingly.
Question No. 6: To whom is the delay of almost eight years, from the institution of the
complaint on 14.05.2012 till the passing of the impugned order dated 18.02.2020, attributable,
and what consequence follows therefrom?
74. The chronology of the present case reveals a delay which cannot be
treated as an ordinary or inconsequential delay. The complaint was
instituted on 14.05.2012, whereas cognizance was taken only on
18.02.2020. Thus, nearly eight years elapsed between institution of the
complaint and issuance of process. During this entire period, the
material issue concerning reanalysis of the sample remained
unresolved, despite the sample having a limited shelf life and despite
the petitioner having exercised its statutory right to seek reanalysis.
75. The impugned order dated 18.02.2020 itself records that after the
complaint was presented on 14.05.2012, no order appeared to have
been recorded and, when the matter subsequently came before the then
learned Chief Judicial Magistrate, a report was obtained from the
concerned clerk. The learned Magistrate noticed that the complaint
appeared to have been presented on 14.05.2012, that one of the samples
had been referred for retesting and that the report was awaited,
whereafter a direction was issued to the concerned clerk to send a
reminder. The relevant part of the impugned order reads as under:
CRM(M) No. 618/2024
―Today during proceedings it revealed that complaint in
question came to be presented before the court on 14.05.2012
but no order appears to have been recorded after presentation
of the complaint and it was only on 19.01.2013 when the
matter came up before the then CJM who obtained report from
the concerned clerk on 14.01.2013 and thereafter observed that
as per the file, the complaint appears to have been presented on
14.05.2012 and one of the sample stands referred for retesting
and the report is awaited and the direction was issued to the
concerned clerk to send reminder. The order of the court dated
14.01 2013 reads as under:‖
76. Significantly, however, the same order refers to the order of the Court
dated 14.01.2013, thereby creating an apparent inconsistency with the
preceding reference to the matter having come up before the learned
CJM on 19.01.2013. Further, the said order dated 14.01.2013, which is
relied upon in the impugned order, has itself not been reproduced or
otherwise brought on record. More importantly, there is no
corresponding official judicial order on record evidencing that the
sample was, in fact, directed to be sent for re-testing to the Central
Drugs Laboratory, Kolkata.
77. Assuming that the sample had been sent when the complaint was
instituted, and considering that its shelf life was only up to July, 2012, it
was incumbent upon the Court and the concerned authorities to ensure
that the sample reached the Central Drugs Laboratory within the period
when it could still be tested. Instead, several years passed with the
Court merely awaiting the report and issuing reminders. The statutory
timeline inherent in the nature of the sample was thus allowed to lapse
without any effective measure being taken to secure compliance.
CRM(M) No. 618/2024
78. The position became even more serious when the Central Drugs
Laboratory, after more than four years, communicated vide report
dated 25.10.2016 that no such sample had been received from the
Court. This was such a response which could not have been easily
digested by the Learned Trial Court. Since the record of the trial Court
indicated otherwise that the sample had been sent to the Central Drugs
Laboratory and the Learned Trial Court ought to have dived deep into
the issue by conducting an inquiry into the actual circumstances in
which the sample failed to reach the Laboratory.
79. However, to the contrary, the Learned Magistrate vide order dated
06.07.2017, merely directed the Drug Inspector to take necessary steps
in light of the report dated 25.10.2016. The record does not disclose any
effective follow-up thereafter. The impugned order dated 18.02.2020
passed by the Court below is conspicuously short of any reasoning as to
what measures were adopted after the report of the Director, Central
Drugs Laboratory, was received in 2016, why the sample had not
reached the Laboratory and what steps were taken to ascertain the
responsibility for such failure.
80. The responsibility in such a situation could not have been placed upon
the petitioner. The petitioner had exercised its statutory right within the
prescribed period and had sought reanalysis while the sample was still
within its shelf life. This Court therefore is of the view that the delay
occurred within the machinery responsible for giving effect to the
statutory procedure. The Drug Inspector, being the complainant, was
also under an obligation as to why the sample had not reached the
CRM(M) No. 618/2024
Central Drugs Laboratory and to ensure compliance with the statutory
requirements.
81. The Learned Trial Court including the concerned clerical machinery,
also had a bounden duty to ensure that the directions for transmission
and follow-up of the sample were effectively complied with. Once, the
Court had sent the sample, and the Central Drugs Laboratory
subsequently stated that it had not received it, it was the bounden duty
of the Court to ascertain what had happened in between, where the
sample had been lost and on whose account the same has been lost.
These questions were required to be gone into in detail and
responsibility, if found, was required to be fastened rather than allowing
the consequences of such failure to fall upon the accused.
82. The fact that the learned Court of Chief Judicial Magistrate, Kathua
continued to await the report for more than four years and after
receiving the Laboratory's response, allowed a further period of four
years to pass until 2020, leading to an inordinate delay of about eight
long years in total, without effectively resolving the issue, shocks the
conscience of this court.
83. The learned trial Court, the clerical staff and the Drug Inspector were
required to ensure compliance with the statutory procedure, which this
Court is afraid to observe was not done. The delay is therefore not
attributable to conduct of the petitioner which could justify denying the
petitioner the benefit of the statutory mechanism it had invoked. The
manner in which the matter proceeded is a stark instance where the
statutory timeline was allowed to become meaningless. A sample
CRM(M) No. 618/2024
having shelf life only up to July, 2012 was followed up for years, the
Central Drugs Laboratory ultimately stated that it had never received
the sample and yet the prosecution was permitted to proceed in 2020 on
the basis of the earlier report. This Court is deeply perturbed to note
the casual manner in which the whole exercise has been done.
84. Therefore, this Court is of the considered view that this issue cannot
end merely with setting aside the entire process but the circumstances
disclosed by the record warrant examination of the entire case
threadbare with a view to fix the responsibility for such inordinate
delay and the failure in transmission of the sample so that, such
incidents do not recur, particularly in matters concerning drugs where
the statutory timelines and shelf life have a direct bearing upon public
health.
Question No. 6 is accordingly answered by holding that the conduct of the
prosecution machinery, the Drug Inspector and the Court authorities
requires examination for fixing responsibility in accordance with law.
Question No. 7: Whether the prolonged pendency of the prosecution, violates the requirement of
a fair and speedy trial under Article 21 of the Constitution of India, particularly when the
prosecution concerns a matter having serious ramifications for public health?
85. It goes without saying that the right to a fair and speedy trial forms an
important component of the guarantee of life and personal liberty under
Article 21 of the Constitution of India. The requirement assumes
particular significance in a criminal prosecution where the accused is
subjected to the continuing burden of criminal proceedings for a
prolonged period and where the passage of time has a direct bearing
upon the right of the accused to effectively defend the prosecution.
CRM(M) No. 618/2024
86. In the present case, admittedly the complaint was instituted on
14.05.2012, whereas process was issued only on 18.02.2020. During
this period, the central issue concerning the reanalysis of the sample
remained unresolved. The delay was not merely a delay in conclusion
of trial. It resulted in the destruction of the very evidentiary opportunity
which the petitioner had sought to avail under Section 25 of the Act.
87. Such a consequence cannot be viewed in isolation from the conduct of
the proceedings. The Court continued to await the report for
approximately eight years and issued only reminders, while the matter
remained without effective resolution until 2020. Besides, the impugned
order also does not disclose any satisfactory explanation for this
prolonged inaction.
88. The fact that the prosecution concerns public health does not dilute the
requirement of a fair and speedy procedure. Indeed, where the
allegation concerns the quality of a drug, it becomes all the more
important that the statutory testing mechanism be completed promptly
and correctly. The interests of the public require a reliable
determination regarding the quality of the drug, while the interests of
the accused require that the statutory opportunity to contest such
determination be preserved.
89. The present case demonstrates how delay can affect both sides of the
statutory scheme. On one hand, prolonged delay defeats the timely
determination of whether the drug was actually of substandard quality;
on the other, it deprives the accused of the opportunity to obtain an
independent
statutory
determination
from
the
Central
Drugs
CRM(M) No. 618/2024
Laboratory. The statutory object cannot be served by allowing both
consequences to follow from an unexplained failure in the process.
90. The requirement of a fair and speedy procedure cannot be satisfied by
keeping the prosecution alive for years and thereafter proceeding on the
basis of an earlier report after the statutory opportunity to test that
report has ceased to exist.
Question No. 7 is accordingly answered by holding that, in the peculiar facts
of the present case, the prolonged delay and resultant deprivation of the
statutory right of defense have materially affected the fairness of the
proceedings and attracted the guarantee of Article 21 of the Constitution.
Question No. 8: Whether, in the facts of the present case, continuation of the prosecution
amounts to abuse of the process of law warranting exercise of the inherent jurisdiction of this
Court under Section 482 of the Code of Criminal Procedure, 1973 akin to Section 528 of the
Bharatiya Nagarik Suraksha Sanhita, 2023 (for short ‗the BNSS‘)?
91. This Court is conscious of the fact that the power under Section 482 of
the Code of Criminal Procedure [akin to Bharatiya Nagarik Suraksha
Sanhita, 2023 (BNSS)] is an extraordinary jurisdiction and is to be
exercised with care and circumspection. However, where the
continuation of a criminal proceeding would result in abuse of the
process of law or where the foundational circumstances necessary for a
fair prosecution have been rendered impossible by the manner in which
the statutory procedure has been dealt with, the inherent jurisdiction of
the Court can be invoked to secure the ends of justice.
92. The Hon’ble Apex Court in “State of Karnataka v. M. Devendrappa
& Anr.”, (2002) 3 SCC 89 while delineating the scope and purpose of
the inherent jurisdiction under Section 482 of the Code of Criminal
Procedure, has held as under:
CRM(M) No. 618/2024
―6…It envisages three circumstances under which the inherent jurisdiction
may be exercised, namely, (i) to give effect to an order under the Code, (ii)
to prevent abuse of process of Court, and (iii) to otherwise secure the ends
of justice….. It is to be exercised exdebite justitiae to do real and
substantial justice for the administration of which alone Courts exist.
Authority of the Court exists for advancement of justice and if any attempt
is made to abuse that authority so as to produce injustice, the Court has
power to prevent abuse. It would be an abuse of process of Court to allow
any action which would result in injustice and prevent promotion of
justice. In exercise of the powers Court would be justified to quash any
proceeding if it finds initiation/continuance of it amounts to abuse of
process of Court or quashing of these proceedings would otherwise serve the
ends of justice…‖
93. Similarly, the Hon’ble Supreme Court in “Hasmukhlal D. Vora &
Anr. Vs. The State of Tamil Nadu”, [2022] 16 S.C.R. 113 , held as
under :
―28. It must be noted that the High Court while passing the impugned
judgment, has failed to take into consideration to the facts and
circumstances of the case. While it is true that the quashing of a criminal
complaint must be done only in the rarest of rare cases, it is still the duty
of the High Court to look into each and every case with great detail to
prevent miscarriage of justice….―
94. This High Court in “Cipla Limited v. State of Jammu & Kashmir and
anr.”, CRMC No.614/2016 decided on 30.09.2022 while relying upon
Medicamen Biotech Limited v. Rubina Bose, (2008) 7 SCC 196, also held as
under:
―18. Relying upon the aforesaid observations, the Supreme Court in
the case of Medicamen Biotech Limited and another v. Rubina Bose
Drug Inspector, (2008) 7 SCC 196 quashed the proceedings on the
ground that the accused in the said case had been deprived of valuable
right under Section 25(3) and 25(4) of the Drugs and Cosmetic Act.
19. From the foregoing analysis of the legal position, it is clear that
once it is established that valuable right of the accused to adduce
evidence in controversion of the Government Analyst's report is
defeated due to acts and omissions of the Drugs Inspector, prosecution
against the accused deserves to be quashed.‖
95. In the present case, the entire exercise undertaken by the learned
Magistrate, commencing with transmission of the sample for reanalysis,
CRM(M) No. 618/2024
followed by waiting for years, receipt of a communication that the
sample had not reached the Central Drugs Laboratory, failure to
inquire into the circumstances leading to such delay and ultimately
issuance of process on the basis of the earlier report, vitiates the
mandate and spirit of the Act. The process issued thereafter cannot be
permitted to sustain.
96. Thus, continuation of the prosecution would therefore require the
petitioner to face criminal proceedings even though the statutory
mechanism for testing the disputed sample was never effectively
completed and the possibility of such testing has since been lost due to
circumstances not attributable to the petitioner. This is a case where
interference under the inherent jurisdiction of this Court is warranted to
prevent abuse of the process of law and to secure the ends of justice.
Accordingly, Question No. 8 is answered in favour of the petitioner and
against the official respondent.
Lapses:
97. The record discloses serious lapses at different stages of the proceedings
which require to be examined separately. At the very inception, the
order passed by the learned Magistrate itself reflects an apparent
inconsistency, inasmuch as the complaint was instituted on 14.05.2012,
whereas the order records that the complaint appeared to have been
presented on that date and that one of the samples had already been
referred for retesting, for which the report was awaited. Be that as it
may, the sample in question had a limited shelf life and was to expire in
July, 2012. Once the petitioner had exercised its statutory right under
CRM(M) No. 618/2024
Section 25 and the sample was required to be sent to the Central Drugs
Laboratory for re-analysis, it was incumbent upon the concerned
authorities and the learned Court to ensure that the sample reached the
Laboratory within the period during which it could have been
meaningfully tested. Instead, the matter was allowed to linger by
merely awaiting the report and issuing reminders, without any effective
measure being taken to ascertain whether the sample had actually
reached the Central Drugs Laboratory.
98. This aspect assumes significance in the light of the statutory scheme
under Section 23 of the Act, whereby the sample is required to be
divided into prescribed portions, including a portion to be produced
before the Court. It therefore needs to be ascertained as to where the
sample was after it was sent by the learned Court, at what stage it
ceased to be traceable and who was responsible for ensuring
compliance with the statutory procedure. For facility of reference
section 23 of the Drugs and Cosmetics Act 1940 is reproduced
hereunder:
―23. Procedure of Inspectors—
(1) Where an Inspector takes any sample of a drug or cosmetic under
this Chapter, he shall tender the fair price thereof and may require a
written acknowledgment therefor.
(2) Where the price tendered under sub-section (1) is refused, or
where the Inspector seizes the stock of any drug or cosmetic under
clause (c) of section 22, he shall tender a receipt therefor in the
prescribed form.
(3) Where an Inspector takes a sample of a drug or cosmetic for the
purpose of test or analysis, he shall intimate such purpose in writing
in the prescribed form to the person from whom he takes it and, in
the presence of such person unless he willfully absents himself, shall
divide the sample into four portions and effectively seal and suitably
mark the same and permit such person to add his own seal and mark
CRM(M) No. 618/2024
to all or any of the portions so sealed and marked:
Provided that where the sample is taken from premises whereon the
drug or cosmetic is being manufactured, it shall be necessary to
divide the sample into three portions only: Provided further that
where the drug or cosmetic is made up in containers of small volume,
instead of dividing a sample as aforesaid, the Inspector may, and if
the drug or cosmetic be such that it is likely to deteriorate or be
otherwise damaged by exposure shall, take three or four, as the case
may be, of the said containers after suitably marking the same and,
where necessary, sealing them.
(4) The Inspector shall restore one portion of a sample so divided or
one container, as the case may be, to the person from whom he takes
it, and shall retain the remainder and dispose of the same as
follows:—
(i) one portion or container he shall forthwith send to the
Government Analyst for test or analysis;
(ii) the second he shall produce to the Court before which
proceedings, if any, are instituted in respect of the drug or
cosmetic; and
(iii) the third, where taken, he shall send to the person, if any, whose
name, address and other particulars have been disclosed under
section 18A.
(5) Where an Inspector takes any action under clause (c) of section
22,—
(a) he shall use all despatch in ascertaining whether or not the drug
or cosmetic contravenes any of the provisions of the section 18
and, if it is ascertained that the drug or cosmetic does not so
contravene, forthwith revoke the order passed under the said
clause or, as the case may be, take such action as may be
necessary for the return of the stock seized;
(b) if he seizes the stock of the drug or cosmetic, he shall as soon as
may be inform a Judicial Magistrate and take his orders as to
the custody thereof;
(c) without prejudice to the institution of any prosecution, if the
alleged contravention be such that the defect may be remedied by
the possessor of the drug or cosmetic, he shall, on being satisfied
that the defect has been so remedied, forthwith revoke his order
under the said clause.
(6) Where an Inspector seizes any record, register, document or any
other material object under clause (cc) of sub- section (1) of
section 22, he shall, as soon as may be, inform a Judicial
Magistrate and take his orders as to the custody thereof.
99. The lapse becomes more serious after the communication dated
25.10.2016 was received from the Central Drugs Laboratory, Kolkata,
CRM(M) No. 618/2024
categorically stating that no such sample had been received from the
Court of the learned Chief Judicial Magistrate, Kathua. At that stage, the
learned Court was confronted with a fundamental failure in the very
statutory mechanism which had been set in motion for protecting the
petitioner's right of re-analysis. The Court was therefore required to
ascertain at that stage how the sample had gone missing and at what stage
it had failed to reach the Laboratory and on whose account, such failure
had occurred, so as to take effective measures for securing compliance
with the statutory procedure.
100. The Learned Magistrate instead, vide order dated 06.07.2017, merely
directed the Drug Inspector to take necessary steps, without any further
effective action being reflected from the record. No inquiry was
undertaken as to the whereabouts of the sample, no responsibility was
fixed and no effective or coercive measure was taken to ascertain why
the report had not been received. The role of the Drug Inspector also
requires examination, particularly as he was the complainant and the
officer through whom the statutory process had commenced, as to
whether he had taken all steps required of him under the statutory
scheme and whether, after the sample was sent for re-analysis, he had
taken appropriate steps to ensure that the statutory process was brought
to its logical conclusion.
101. The position becomes still more inexplicable when the subsequent
conduct of the learned Court is examined. Despite having been
informed in the year 2016 that the Central Drugs Laboratory had not
received the sample and despite the order dated 06.07.2017 directing
CRM(M) No. 618/2024
the Drug Inspector to take necessary steps, no effective proceedings
were undertaken till the year 2020. The learned Magistrate ultimately
passed the impugned order dated 18.02.2020 and took cognizance on
the basis of the earlier report of the Government Analyst, although by
then the sample had already expired in July, 2012 i.e. almost eight
years earlier. The impugned order does not disclose what steps were
taken between 2016 and 2020 to ascertain the fate of the sample, why
the failure of the sample to reach the Central Drugs Laboratory was not
investigated, or how the prosecution could meaningfully proceed once
the sample had lost its shelf life.
102. Once the sample had expired, the question whether it had actually been
sent to Central Drugs Laboratory, Kolkata or lost midway, assumed
even greater significance, because the opportunity for meaningful reanalysis had become irretrievably lost. The matter thus discloses lapses
both before and after the year 2016, which falls exclusively within the
domain of learned Court and its clerical staff and also the Drug
Inspector, which requires to be specifically examined and responsibility
is also required to be fixed. Such examination is all the more necessary
as the proceedings concern the quality and safety of a drug and any
serious lapse in ensuring timely compliance with the statutory
mechanism may have direct and serious ramifications for public health.
103. This is a rare case which shocks the judicial conscience of this Court,
where a sample stated to have been sent by the Court to the Central
Drugs Laboratory was not received by the said Laboratory for almost
eight years, while the Court continued to await the report without
CRM(M) No. 618/2024
taking any effective or coercive measures to secure the same or
examining the circumstances in which the sample had failed to reach
the Laboratory. After waiting for such an inordinate period, the learned
trial Court proceeded to rely upon the earlier report of the Government
Analyst and issued process on the basis thereof, notwithstanding that
the said report had lost its significance in the peculiar facts and
circumstances of the case. Equally significant is the fact that the sample
had a limited shelf life and had already expired in July, 2012, yet the
proceedings continued for several years thereafter without any effective
determination as to how and why the statutory process remained
incomplete. Once the validity of the sample had expired in July, 2012,
the question as to how and under what circumstances the proceedings
before the learned trial Court continued for almost eight years
thereafter, and what legal sanctity could attach to such proceedings in
the absence of the very sample being available for re-analysis, requires a
thorough examination. The matter, therefore, warrants a threadbare
inquiry into the circumstances leading to the non-receipt of the sample
by the Central Drugs Laboratory, the prolonged inaction thereafter, and
the responsibility for permitting the proceedings to continue despite the
expiry of the sample.
Conclusion:
104. In view of the foregoing discussion, the impugned order dated
18.02.2020 passed by the learned Chief Judicial Magistrate, Kathua,
whereby cognizance was taken and process was issued against the
petitioner, along with the consequential proceedings arising therefrom,
CRM(M) No. 618/2024
cannot sustain and are accordingly quashed qua the petitioner.
However, having regard to the serious lapses noticed in the handling
and transmission of the sample, and the fact that time is of the essence
under the statutory scheme governing Drugs and Cosmetics Act, 1940
this Court deems it appropriate that the matter be examined on the
administrative side so that such lapses do not recur.
105. Accordingly, the learned Registrar General of this Court shall place the
judgment passed by this Court alongwith the complete paper-book of
the instant case and the entire scanned record of the Learned Trial
Court before Hon’ble the Chief Justice on the administrative side for
appropriate action.
106. In addition, the Drug Controller, Drugs and Food Control
Organization, J&K, Jammu shall also constitute a Committee within
one week from today headed by him and he will be at liberty to co-opt
two members having requisite expertise in the Drugs and Cosmetics
Act and the statutory procedure governing testing and analysis of drug
samples.
107. The said Committee shall examine the lapses noticed in the present
case and fix the responsibility for the same, whether there was any lapse
or negligence on the part of the Drug Inspector or any other officer
concerned with the matter and also to ascertain the reasons why the
sample once dispatched by the competent Court has not reached the
Central Drugs Laboratory, Kolkata. The committee shall also inquire
whether there was any mischief or role played by any official of the
petitioner-Company in manipulating the record with the intention that
CRM(M) No. 618/2024
the sample should not reach before the Central Drugs Laboratory,
Kolkata by providing an opportunity of being heard to all the
stakeholders. The entire exercise shall be undertaken within four weeks
from the date of the constitution of the Committee so that such lapses
do not recur in future, particularly as time is of the essence under the
statutory scheme and any serious lapse in matters concerning the
testing of drugs may have a direct bearing upon public health. The
Drug Controller shall submit its report in a sealed cover before the
Registrar Judicial of this Court thereafter.
108. The Registry shall place the said report of the Drug Controller before
this Court by way of index for further appropriate action.
109. The petition is, accordingly, allowed in the aforesaid terms.
110. Registry is directed to provide complete paper book of the instant case
along with the entire scanned record of the learned Trial Court before
Learned Registrar General of this Court and also to Drug Controller,
Drugs and Food Control Organization, J&K, Jammu forthwith.
(WASIM SADIQ NARGAL)
JUDGE
JAMMU
18.08.2026
Vijay
Whether the judgment is speaking : Yes
Whether the judgment of reportable: Yes
Vijay Kumar
2026.08.18 22.35
I attest to the accuracy and
integrity of this document
Jammu
This page is for informational and research purposes only and does not constitute legal advice.
Consult a qualified advocate for advice specific to your situation.
Is your name in this judgment and should it be masked, or is something on this page wrong?
Request a review